# US 2002/0177764 A1 · Monitoring analyte concentration using minimally invasive devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0177764 A1
- Document ID: US20020177764A1
- Status: Published application
- Kind: A1
- Application number: 09/865,826
- Filed: 2001-05-25
- Published: 2002-11-28
- Earliest claimed: 2001-05-25
- Assignees: LifeScan, Inc.
- Inventors: Borzu Sohrab
- Web page: https://patentgrep.com/patent/US20020177764A1

## CPC

- A61B 5/681: {Wristwatch-type devices}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/66: involving blood sugars, e.g. galactose
- A61B 5/0002: {Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network (endoradiosondes A61B5/07)}
- A61B 5/14514: {using means for aiding extraction of interstitial fluid, e.g. microneedles or suction}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and devices are provided for “continuously”monitoring the concentration of an analyte in a host, i.e., for automatically measuring the concentration of an analyte at two or more points during a given time period. In the subject methods, substantially painless single use analyte concentration detection devices are employed to measure the concentration of the analyte of interest in the host, or portion thereof, e.g., interstitial fluid, where the measurements take place automatically according to a predetermined schedule. Devices provided by the subject methods have at least two different substantially painless single use analyte concentration measurement components which are under the control of a processing means that activates the measurement components according to a predetermined schedule. Also provided are systems and kits for use in practicing the subject methods. The subject methods find use in monitoring the concentration of a variety of different analytes of interest, and are particularly suited for use in monitoring the concentration of glucose.

## Claims

### Claim 1

A method of monitoring the concentration of an analyte in a host or portion thereof over a given time period, said method comprising:
(a) making a first analyte concentration measurement in said host or portion thereof at a first point in said time period using a first substantially painless single use analyte concentration measurement means;
(b) making a second analyte concentration measurement in said host or portion thereof at a second point in said time period using a second substantially painless single use analyte concentration measurement means; and
(c) optionally making one or more additional analyte concentration measurements during said time period using one or more additional substantially painless single use analyte concentration measurement means;
wherein said analyte concentration measurements are made according to a selected scheduling mode to monitor the concentration of said analyte in said host or portion thereof over said given time period.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said host or portion thereof is interstitial fluid.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said substantially painless single use analyte concentration measurement means is an interstitial fluid analyte measurement means.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said interstitial fluid analyte measurement means makes an in situ analyte concentration measurement.

### Claim 5 (depends on 3)

The method according to claim 3, wherein said interstitial fluid analyte measurement means makes an ex vivo analyte concentration measurement.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said interstitial fluid analyte concentration measurement means removes interstitial fluid from said host and analyzes said fluid outside of said host.

### Claim 7 (depends on 3)

The method according to claim 3, wherein said interstitial fluid analyte concentration measurement means comprises a microneedle.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said analyte is glucose.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the selected scheduling mode comprises a predetermined schedule.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the predetermined schedule comprises measurements taken at fixed time intervals.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the predetermined schedule comprises measurements taken at fixed times.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the selected scheduling mode comprises a scheduling mode responsive to previously collected analyte concentration measurements.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the previously collected analyte concentration measurements were taken over the previous 48 hours.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the previously collected analyte concentration measurements were taken over the previous two hours or less.

### Claim 15

A method of monitoring the concentration of glucose in interstitial fluid of a host over a given time period, said method comprising:
(a) making a first interstitial fluid glucose concentration measurement at a first point in said time period using a first substantially painless single use interstitial fluid glucose concentration measurement means;
(b) making a second interestitial fluid glucose concentration measurement at a second point in said time period using a second substantially painless single use interestitial fluid glucose concentration measurement means; and
(c) optionally making one or more additional interstitial fluid glucose concentration measurements during said time period using one or more additional substantially painless single use interestitial fluid glucose concentration measurement means;
wherein said interstitial fluid glucose concentration measurements are made according to a predetermined schedule to monitor the concentration of interstitial fluid glucose over said given time period.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said interstitial fluid glucose measurement means makes an in situ measurement.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said interstitial fluid glucose measurement means makes an ex vivo measurement.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said interstitial fluid glucose concentration measurement means removes interstitial fluid from said host and analyzes said fluid outside of said host.

### Claim 19 (depends on 15)

The method according to claim 15, wherein said interstitial fluid glucose concentration measurement means comprises a microneedle.

### Claim 20 (depends on 15)

The method according to claim 15, wherein said method employs a device that comprises:
(a) at least said first and second substantially painless interstitial fluid glucose measurement means; and
(b) an activation means that activates said first and second measurement means according to a predetermined schedule.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said activation means comprises hardware and software components that activate said first and second measurement means according to said predetermined schedule.

### Claim 22

A device for using in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said device comprising:
(a) at least a first and a second substantially painless single use analyte concentration measurement means; and
(b) an activation means for selectively activating said first and second analyte concentration measurement means according to a predetermined schedule.

### Claim 23 (depends on 22)

The device according to claim 22, wherein said activation means comprises hardware and software components that activate said first and second measurement means according to said predetermined schedule.

### Claim 24 (depends on 22)

The device according to claim 22, wherein said substantially painless analyte concentration measurement means are interstitial fluid analyte concentration measurement means.

### Claim 25 (depends on 24)

The device according to claim 24, wherein said interstitial fluid analyte concentration measurement means are glucose concentration measurement means.

### Claim 26 (depends on 24)

The device according to claim 24, wherein said interstitial fluid analyte concentration measurement means comprise a microneedle.

### Claim 27 (depends on 22)

The device according to claim 22, wherein said device comprises a removable cartridge that comprises said first and second analyte concentration measurement means.

### Claim 28

A system for use in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said system comprising:
(a) a removable cartridge comprising at least a first and a second substantially painless single use analyte concentration measurement means; and
(b) a device into which said cartridge may be inserted, wherein said device comprises an activation means for selectively activating said first and second measurement means of said cartridge according to a predetermined schedule.

### Claim 29 (depends on 28)

The system according to claim 28, wherein said activation means comprises hardware and software components that activate said first and second measurement means according to said predetermined schedule.

### Claim 30 (depends on 28)

The system according to claim 28, wherein said substantially painless analyte concentration measurement means of said cartridge are interstitial fluid analyte concentration measurement means.

### Claim 31 (depends on 30)

The system according to claim 30, wherein said interstital fluid analyte concentration measurement means are glucose concentration measurement means.

### Claim 32 (depends on 30)

The system according to claim 30, wherein said interstitial fluid analyte concentration measurement means comprise a microneedle.

### Claim 33

A kit for use in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said kit comprising:
at least one of:
(a) a removable cartridge comprising at least a first and a second substantially painless single use analyte concentration measurement means; and
(b) a device into which said cartridge may be inserted, wherein said device comprises a an activation means for selectively activating said first and second measurement means of said cartridge according to a predetermined schedule.

### Claim 34 (depends on 33)

The kit according to claim 33, wherein said activation means comprises hardware and software components that activate said first and second measurement means according to said predetermined schedule.

### Claim 35 (depends on 33)

The kit according to claim 33, wherein said substantially painless analyte concentration measurement means of said cartridge are interstitial fluid analyte concentration measurement means.

### Claim 36 (depends on 35)

The kit according to claim 35, wherein said interstitial fluid analyte concentration measurement means are glucose concentration measurement means.

### Claim 37 (depends on 35)

The kit according to claim 35, wherein said interstitial fluid analyte concentration measurement means comprise a microneedle.

### Claim 38 (depends on 33)

The kit according to claim 33, wherein said kit further comprises a second cartridge.

### Claim 39 (depends on 33)

The kit according to claim 33, wherein said kit further comprises instructions for using said kit in monitoring the concentration of an analyte over a period of time.
